Marcaine 0.25 % Injectable Solution — Competitive Intelligence Brief

Marcaine 0.25 % Injectable Solution (Marcaine 0.25 % Injectable Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic. Area: Anesthesia.

marketed Local anesthetic Voltage-gated sodium channels Anesthesia Small molecule

Target snapshot

Marcaine 0.25 % Injectable Solution (Marcaine 0.25 % Injectable Solution) — Connecticut Children's Medical Center. Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Marcaine 0.25 % Injectable Solution TARGET	Marcaine 0.25 % Injectable Solution	Connecticut Children's Medical Center	marketed	Local anesthetic	Voltage-gated sodium channels
Buffered Lidocaine	Buffered Lidocaine	University of California, San Diego	marketed	Local anesthetic	Voltage-gated sodium channels
ropivacaine and ketorolac	ropivacaine and ketorolac	University of Aarhus	marketed	Local anesthetic + NSAID combination	Voltage-gated sodium channels (ropivacaine); COX-1 and COX-2 (ketorolac)
Bupivacaine and Fentanyl	Bupivacaine and Fentanyl	Bnai Zion Medical Center	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu-opioid receptor (fentanyl)
Bupivacaine-fentanyl elective group	Bupivacaine-fentanyl elective group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic with opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
Remifentanil+Lidocaine	Remifentanil+Lidocaine	The First Affiliated Hospital of Zhengzhou University	marketed	Opioid analgesic + Local anesthetic combination	Mu-opioid receptor (remifentanil); Voltage-gated sodium channels (lidocaine)
intraarticular injection with ropivacaine	intraarticular injection with ropivacaine	Hvidovre University Hospital	marketed	Local anesthetic	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic class)

1. University of California, San Diego · 3 drugs in this class
2. Durect · 3 drugs in this class
3. Pacira Pharmaceuticals, Inc · 3 drugs in this class
4. Wake Forest University Health Sciences · 3 drugs in this class
5. Medical University of Vienna · 3 drugs in this class
6. Imperial College London · 2 drugs in this class
7. Hvidovre University Hospital · 2 drugs in this class
8. Innocoll · 2 drugs in this class
9. George Washington University · 2 drugs in this class
10. Guy's and St Thomas' NHS Foundation Trust · 2 drugs in this class